Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ZL006 is an inhibitor of the protein-protein interaction between neuronal nitric oxide synthase (nNOS) and postsynaptic density protein-95 (PSD-95).1 It inhibits NMDA-induced lactate dehydrogenase release (IC50 = 0.082 µM), as well as glutamate and glycine-induced, NMDA receptor-dependent production of nitric oxide (NO), in primary mouse neurons. ZL006 (1.5 mg/kg) prevents ischemia-induced increases in nNOS-PSD-95 complex formation in cortices isolated from a mouse model of ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO). It reduces infarct size and increases survival in the same model. ZL006 suppresses mechanical and cold allodynia in a mouse model of neuropathic pain induced by paclitaxel (Item No. 10461).2
WARNING This product is not for human or veterinary use.
1. Treatment of cerebral ischemia by disrupting ischemia-
2. Small molecule inhibitors of PSD95-